



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
20 September 2021
3 September 2021

#### Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Andrew Robert Donald SOMERVELL
Fisher & Paykel Healthcare Corporation Limited
Not Applicable
Vice President - Products & Technology

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

Exercise of Performance Share Rights
Beneficial

##### For that relevant interest

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

35,676 PSRs
80,779 ordinary shares
25,656 PSRs
90,799 ordinary shares
Andrew Robert Donald Somervell
Andrew Robert Donald Somervell

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Not Applicable
----------------

##### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


##### For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:
---

One
-----

**Details of transactions requiring disclosure-**

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

17-Sep-21
Exercise of PSRs
Issue of shares
\$nil (converted to shares)
Exercise of 10,020 PSRs
Issue of 10,020 ordinary shares

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest,-</i>
Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest,-</i>
Type of derivative:


Options
Beneficial
109,826
Andrew Somervell
Not applicable

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Cerification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:


20 September 2021



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
20 September 2021
3 September 2021

#### Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

<b>Lewis George GRADON</b>
Fisher & Paykel Healthcare Corporation Limited
Chief Executive Officer

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
<b>For that relevant interest:</b>
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) Options to acquire Ordinary Shares (b) Performance Share Rights (c) Ordinary Shares
Beneficial Interest
(a) 382,704 Options to acquire Ordinary Shares (b) 124,253 Performance Share Rights (c) 556,776 Ordinary Shares
(a) 282,391 Options to acquire Ordinary Shares (b) 91,787 Performance Share Rights (c) 562,280 Ordinary Shares
Lewis George Gradon and Gradon Family Trust
Lewis George Gradon and Gradon Family Trust

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:
<b>Details of affected derivative:</b>
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative:</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Not Applicable

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:
<b>Details of transactions requiring disclosure:</b>
Date of transaction:


Three
(a) 16 September 2021 (b) 16 September 2021 (c) 16 September 2021

Nature of transaction:	(a) Exercise of options to acquire ordinary shares (b) Exercise of Performance Share Rights (c) Sale of ordinary shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:	(a) \$nil (b) \$nil (c) \$2,497,192
Number of financial products to which the transaction related:	(a) 100,313 options; 53,038 ordinary shares (b) 32,466 (c) 80,000
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:</i>	
Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

#### Summary of other relevant interests after acquisition or disposal

Class of quoted financial products:	
Nature of relevant interest:	
<i>For that relevant interest:</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest:</i>	
Type of derivative:	Not Applicable
<b>Details of derivative:</b>	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest:</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

#### Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	20 September 2021
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
20 September 2021
3 September 2021

#### Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Paul Nigel Shearer
Fisher & Paykel Healthcare Corporation Limited
Senior Vice President - Sales & Marketing

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
<b>For that relevant interest-</b>
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) Options to acquire Ordinary Shares
(b) Performance Share Rights
(c) Ordinary Shares
Beneficial
(a) 192,112 Options
(b) 62,388 PSRs
(c) 356,460 Ordinary Shares
(a) 136,384 Options
(b) 44,352 PSRs
(c) 384,809 Ordinary Shares
Paul Nigel Shearer and Shearer Family Trust
Paul Nigel Shearer and Shearer Family Trust

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Not Applicable
----------------

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:


#### For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:

Three

**Details of transactions requiring disclosure-**

Date of transaction:

(a) 14 September 2021

(b) 17 September 2021

(c) 15 &amp; 17 September 2021

Nature of transaction:

(a) Issue of Options to acquire Ordinary Shares

(b) Exercise of Performance Share Rights

(c) Sale of Ordinary Shares

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

(a) \$nil

(b) \$nil

(c) \$632,180

Number of financial products to which the transaction related:

(a) 55,728 options; 30,313 ordinary shares

(b) 18,036

(c) 20,000

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:

Nature of relevant interest:

*For that relevant interest, -*

Number held in class:

Current registered holder(s):

*For a derivative relevant interest, -*

Type of derivative:

Not Applicable

**Details of derivative, -**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

*For that derivative relevant interest, -*

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Paul Shore

Date of signature:

20 September 2021

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person: